Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Director departure
Quarterly results
Appointed director

Statera Biopharma, Inc. (CBLI) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/03/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
02/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
02/01/2023 8-K Quarterly results
02/01/2023 8-A12G Form 8-A12G - Registration of securities [Section 12(g)]:
01/20/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
11/28/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
11/18/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
11/15/2022 8-K Quarterly results
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/04/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: " ",
" "
11/04/2022 D Form D - Notice of Exempt Offering of Securities:
10/28/2022 10-Q Quarterly Report for the period ended June 30, 2022
10/27/2022 8-K Quarterly results
10/24/2022 8-K Quarterly results
10/21/2022 10-Q Quarterly Report for the period ended March 31, 2022
10/17/2022 8-K Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T...
Docs: " "
10/05/2022 10-K Annual Report for the period ended December 31, 2021
09/27/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/03/2022 8-K Changes in Registrant's Certifying Accountant, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: " "
06/22/2022 8-K Quarterly results
06/06/2022 8-K Quarterly results
05/27/2022 8-K Quarterly results
04/27/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod FORT COLLINS, CO., April 13, 2022 /Globe Newswire/ — Statera Biopharma , a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company has agreed to enter into a strategic agreement with Coeptis Therapeutics, Inc. , a biopharmaceutical company developing innovative cell therapy platforms for cancer, to sell Statera’s rights to Entolimod and other related toll-like receptor 5 agonists. The consummation of the transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a contingency on Coeptis financing. “Coeptis’ commitment to cancer the..."
04/15/2022 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
04/13/2022 8-K/A Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
03/31/2022 8-K Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran...
Docs: "Resignation Letter of Randy Saluck"
03/31/2022 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
03/25/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
03/23/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/22/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: " "
03/22/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/08/2022 8-K/A Quarterly results
02/25/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy